Laboratory of Immunology, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Université Paris VII, Paris, France.
Bone Marrow Transplant. 2010 Mar;45(3):442-9. doi: 10.1038/bmt.2009.179. Epub 2009 Jul 27.
CD4(+) T-cell functions that best correlate with CMV control were evaluated by studying the relationship between CMV infection and CMV-specific immune recovery as determined by proliferation assay and intracytoplasmic-IFNgamma assay. A total of 30 children (mean age: 8.30 years) who received an allogeneic hematopoietic SCT (HSCT) were included. In total, 13 recipients were seronegative before HSCT. None developed CMV infection or CMV-specific immunity. A total of 17 recipients were seropositive: (i) four patients spontaneously controlled CMV. The median of CMV-specific IFNgamma-secreting CD4 T cells was 9.13/microl at month 3 in these four patients and three of the four patients evidenced optimal proliferative responses since month 1; (ii) in 10 patients who received anti-CMV chemotherapy because of prolonged viremia, lower (P=0.016) IFNgamma responses (0.39/microl), together with delayed and/or depressed proliferative responses, were observed; (iii) finally, one patient with early CMV-associated disease had undetectable proliferative and IFNgamma responses until month 3. In conclusion, both intense IFNgamma responses and early proliferative responses seem to be associated with optimal CMV control.
我们通过研究细胞增殖试验和细胞内 IFNγ 检测评估与 CMV 控制相关性最佳的 CD4(+)T 细胞功能，以评估 CMV 感染与 CMV 特异性免疫恢复之间的关系。共纳入 30 例接受异基因造血干细胞移植（HSCT）的儿童（平均年龄：8.30 岁）。共有 13 例受者在 HSCT 前血清学阴性。他们均未发生 CMV 感染或 CMV 特异性免疫。共有 17 例受者血清学阳性：（i）4 例患者自发性控制 CMV。这 4 例患者在第 3 个月时 CMV 特异性 IFNγ 分泌 CD4 T 细胞的中位数为 9.13/µl，其中 3 例患者从第 1 个月开始就表现出最佳的增殖反应；（ii）在因持续病毒血症而接受抗 CMV 化疗的 10 例患者中，IFNγ 反应（0.39/µl）较低（P=0.016），同时观察到增殖反应延迟和/或抑制；（iii）最后，1 例出现早期 CMV 相关性疾病的患者在第 3 个月之前增殖和 IFNγ 反应均无法检测到。总之，强烈的 IFNγ 反应和早期增殖反应似乎都与最佳 CMV 控制有关。
